



**THERMOGENESIS CORP. TO ANNOUNCE SECOND QUARTER  
FISCAL 2007 RESULTS ON FEBRUARY 9, 2007**

**RANCHO CORDOVA, Calif. – (February 2, 2007) – ThermoGenesis Corp. (NASDAQ: KOOL)**, a company that designs and develops enabling technologies for cell therapy and surgical wound care, announced today it will report financial results for the fiscal second quarter ended December 31, 2006, on Friday, February 9, 2007.

**Conference Call and Webcast**

Management will host a conference call Friday, February 9, 2007 at 11:00 AM Pacific (2:00 PM Eastern) to review the fiscal second quarter financial results.

The call can be accessed by dialing **800-860-2442** within the U.S. or **412-858-4600** outside the U.S. and referencing, "ThermoGenesis." Philip Coelho, Chairman & Chief Executive Officer, William Osgood, General Manager of Operations and Matthew Plavan, Chief Financial Officer will host the call to discuss the second quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.

The conference call will also be available via the Internet at [http://www.thermogenesis.com/investor\\_relations/index.asp](http://www.thermogenesis.com/investor_relations/index.asp)

**Replay**

A replay of the conference call will be available two hours after the call for the following five business days by dialing **877-344-7529 within the U.S. or 412-317-0088 outside the U.S.** and entering the following account number when prompted '385107'.

**About ThermoGenesis Corp.**

ThermoGenesis Corp. ([www.thermogenesis.com](http://www.thermogenesis.com)) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

- **The BioArchive(R) System**, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant. GE Healthcare is the non-exclusive global distribution partner for the BioArchive System.
- **The AutoXpress System (AXP™)** is a newly developed semi-automated device and companion sterile closed blood processing disposable, to harvest stem cells from

cord blood. GE Healthcare is the exclusive global distribution partner for the AXP AutoXpress System.

· **The CryoSeal(R) FS System**, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. A 150-patient U.S. pivotal clinical trial has been completed and a pre-market approval application (PMA) is being reviewed by the FDA. The CryoSeal FS System has received the CE-Mark. From a marketing perspective, the CE Mark is the European equivalent to an FDA approval, in that it allows sales of the product throughout the European community.

· **The Thrombin Processing Device™ (TPD™)** is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The CE Marked TPD is currently being marketed in Europe by Biomet, Inc., subsidiary Biomet Biologics, Medtronic, Inc. and independent distributors.

*This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2007, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2007. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.*

**ThermoGenesis Corp.**

Web site: <http://www.ThermoGenesis.com>

Contact: Fern Lazar of Lazar Partners

+1-212-867-1762